[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

RU2000129671A - Производные 3-(амино- или аминоалкил) пиридинона и их применение для лечения болезней, связанных с ВИЧ - Google Patents

Производные 3-(амино- или аминоалкил) пиридинона и их применение для лечения болезней, связанных с ВИЧ

Info

Publication number
RU2000129671A
RU2000129671A RU2000129671/04A RU2000129671A RU2000129671A RU 2000129671 A RU2000129671 A RU 2000129671A RU 2000129671/04 A RU2000129671/04 A RU 2000129671/04A RU 2000129671 A RU2000129671 A RU 2000129671A RU 2000129671 A RU2000129671 A RU 2000129671A
Authority
RU
Russia
Prior art keywords
alkyl
pyridinone
amino
substituted
group
Prior art date
Application number
RU2000129671/04A
Other languages
English (en)
Inventor
Эмиль БИЗАНИ (FR)
Эмиль БИЗАНИ
Валери ДОЛЛЬ (FR)
Валери ДОЛЛЬ
Чи Хунг НГУЙЕН (FR)
Чи Хунг НГУЙЕН
Клод МОННРЕ (FR)
Клод МОННРЕ
Давид ГРИЕРСОН (FR)
Давид ГРИЕРСОН
Анн-Мари ОБЕРТЕН (FR)
Анн-Мари ОБЕРТЕН
Original Assignee
Сантр Насьональ Де Ля Решерш Сьентифик (Fr)
Сантр Насьональ Де Ля Решерш Сьентифик
Энститю Кюри (Fr)
Энститю Кюри
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сантр Насьональ Де Ля Решерш Сьентифик (Fr), Сантр Насьональ Де Ля Решерш Сьентифик, Энститю Кюри (Fr), Энститю Кюри filed Critical Сантр Насьональ Де Ля Решерш Сьентифик (Fr)
Publication of RU2000129671A publication Critical patent/RU2000129671A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (10)

1. Соединение формулы (1)
Figure 00000001
в которой Q означает -NR1R2 или -R0NR1R2, где R0 означает C1-6-алкандиил, R1 и R2 независимо означают C1-6-алкил или С3-6-алкенил; причем C1-6-алкил и С3-6-алкенил могут быть замещены одним, двумя или тремя заместителями, выбранными из гидрокси, C1-4-алкилокси, C1-4-алкилтио, арилокси, арилтио, амино, моно- или ди(С1-4-алкил) амино и арильной групп, или же R1 и R2 вместе могут образовывать двухвалентный радикал -R1-R2-, представляющий собой - (СН2)2-O-(СН2)2-, -(CH2)2-NR7-(СН2)2-, -(CH2)2-CH(NHR7)-(CH2)2- или -(СН2)n-, где R7 означает водород или C1-4-алкил, а n=2, 3, 4, 5 или 6;
R3 означает арил или моноциклический или бициклический гетероцикл, выбранный из пиридинила, пиримидинила, тиазолинила, фуранила, тиенила, имидазолила, бензоксазолила, бензотиазолила и бензимидазолила, причем эти моноциклические или бициклические гетероциклы необязательно могут быть замещены одним, двумя или тремя заместителями, независимо выбранными из гидрокси, C1-4-алкила, C1-4-алкокси, галоида, трифторометила, диметиленокси или фенильной групп; R4 и R5 независимо означают водород, C1-6-алкил, С3-6-алкенил, C1-4-алкокси, С1-4-алкилокси-С1-4-алкил, амино, моно- или ди(С1-4-алкил) амино, формил, C1-4-алкилкарбонил, карбоксил, C1-4-алкилоксикарбонил или C1-4-алкиламинокарбонил, где C1-6-алкил и С3-6-алкенил могут быть замещены одним, двумя или тремя заместителями, выбранными из гидрокси, C1-4-алкилокси, C1-4-алкилтио, арилокси, арилтио, амино, моно- или ди (C1-4-алкил) амино и арильной групп, или же R4 и R5 вместе образуют двухвалентный радикал формулы -R4-R5-, представляющий собой -СН=СН-СН=СН- или -(CH2)t-, где t=3 или 4;
R6 означает водород, гидрокси, C1-4-алкилокси, C1-6-алкил, С3-6-алкенил, арил, C1-4-алкил, амино, моно- или ди(С1-4-алкил) амино или алкиларил;
Y означает О или S;
Х означает радикал формулы
-(СН2)р- (а) или
-(CH2)q-Z-(CH2)r- (b)
где р=1, 2, 3, 4 или 5;
q=0, 1, 2, 3, 4 или 5;
r=0, 1, 2 или 3;
Z означает NR8, C=O, CHOH, CHNR8R9, CF2, О, S или СН=СН, где R8 и R9 независимо представляют собой водород или C1-4-алкил;
“арил” означает фенил или замещенный фенил с одним, двумя или тремя заместителями, выбранными из C1-4-алкила, C1-4-алкилокси, галоида и трифторометильной группы, или N-оксиды,
их стереохимические изомерные формы или фармацевтически приемлемые комплексные соли.
2. Соединение по п.1, в котором R1 и R2 означают метильную группу.
3. Соединение по п.1, в котором Х означает -СН2-,R3 представляет собой фенильную группу, замещенную двумя метильными группами.
4. Соединение по п.1, представляющее собой 3-диметиламино-4-(3,5-диметилбензил)-5-этил-6-метилпиридин-2 (1Н)-он.
5. Соединение по п.1 для производства фармацевтической композиции для лечения заболеваний, связанных с ВИЧ.
6. Соединение по п.1 для производства фармацевтической композиции для лечения ВИЧ-инфекции.
7. Способ получения соединений по п.1, где Х представляет собой -СН2-, Y означает О, R3 является необязательно замещенной фенильной группой, R6 -водород, включающий следующие стадии: a) взаимодействие пиридина (2), замещенного в положении 2 алкоксигруппой, в положении 3 амидоалкильной группой, с C1-C6 алкиллитием, с получением литиевого производного пиридина, b) превращение литиевого производного в медьорганический реагент путем реакции его с комплексом, образованным CuI и диметилсульфидом, c) получение пиридинона, имеющего защитные группы, путем реакции медьорганического реагента с необязательно замещенным бензилгалидом, d) гидролиз пиридинона, имеющего защитные группы, и получение пиридинона, лишенного защитных групп, e) замещение 3-аминогруппы лишенного защитных групп пиридинона, и получение требуемого соединения пиридинона.
8. Способ получения соединений по п.1, где Х представляет собой -С=О, Y представляет О, R3 является необязательно замещенной фенильной группой, R6 -водород, включающий a) взаимодействие пиридина, замещенного в положении 2 алкоксигруппой, в положении 3 амидоалкильной группой, с C1-С6 алкиллитием, с получением литиевого производного пиридина, b) взаимодействие литиевого производного с необязательно замещенным бензальдегидом, с получением замещенного пиридинона, c) окисление указанного замещенного пиридинона, с образованием пиридинона, имеющего защитные группы, d) удаление защитных групп, введенных в пиридинон, путем гидролиза с образованием требуемого соединения пиридинона.
9. Литиевое производное, имеющее следующую формулу:
Figure 00000002
в которой R4 и R5 определены в п.1 R10 и R11 независимо являются C1-С6-алкилами.
10. Фармацевтическая композиция, включающая терапевтически эффективное количество по крайней мере одного соединения по п.1 и фармацевтически применимые носители.
RU2000129671/04A 1998-04-27 1999-04-27 Производные 3-(амино- или аминоалкил) пиридинона и их применение для лечения болезней, связанных с ВИЧ RU2000129671A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8308298P 1998-04-27 1998-04-27
US60/083,082 1998-04-27

Publications (1)

Publication Number Publication Date
RU2000129671A true RU2000129671A (ru) 2004-02-20

Family

ID=22176061

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2000129671/04A RU2000129671A (ru) 1998-04-27 1999-04-27 Производные 3-(амино- или аминоалкил) пиридинона и их применение для лечения болезней, связанных с ВИЧ

Country Status (27)

Country Link
US (2) US6451822B1 (ru)
EP (1) EP1073637B1 (ru)
JP (1) JP2002513004A (ru)
KR (1) KR20010087128A (ru)
CN (1) CN1303378A (ru)
AP (1) AP2000001991A0 (ru)
AT (1) ATE334966T1 (ru)
AU (1) AU4137899A (ru)
BG (1) BG104984A (ru)
BR (1) BR9909976A (ru)
CA (1) CA2330304A1 (ru)
CZ (1) CZ20003978A3 (ru)
DE (1) DE69932611T2 (ru)
EE (1) EE200000620A (ru)
HR (1) HRP20000716A2 (ru)
HU (1) HUP0101595A3 (ru)
ID (1) ID27502A (ru)
IL (1) IL139239A0 (ru)
MX (1) MXPA00010490A (ru)
NO (1) NO20005387L (ru)
NZ (1) NZ508297A (ru)
PL (1) PL343685A1 (ru)
RU (1) RU2000129671A (ru)
SK (1) SK16072000A3 (ru)
TR (1) TR200003113T2 (ru)
WO (1) WO1999055676A1 (ru)
ZA (1) ZA200006037B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA013740B1 (ru) * 2004-09-17 2010-06-30 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Новые пиридиноновые производные и их применение в качестве позитивных аллостерических модуляторов mglur2-рецепторов

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436972B1 (en) * 2000-04-10 2002-08-20 Dalhousie University Pyridones and their use as modulators of serine hydrolase enzymes
AU2001282938A1 (en) * 2000-07-21 2002-02-05 Elan Pharmaceuticals, Inc. Alpha amino acid derivatives--inhibitors of leukocyte adhesion mediated by vla-4
DE60117839T2 (de) * 2000-09-19 2006-11-23 Institut Curie Pyridinon und pyridinethion-derivate mit hiv-hemmenden eigenschaften
EP1465869B1 (en) 2001-12-21 2013-05-15 Exelixis Patent Company LLC Modulators of lxr
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
US7642277B2 (en) * 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
JP4485520B2 (ja) * 2003-03-24 2010-06-23 エフ．ホフマン−ラ ロシュ アーゲー 逆転写酵素阻害剤としてのベンジル−ピリダジノン類
EP1516873A1 (en) * 2003-09-22 2005-03-23 Facultés Universitaires Notre-Dame de la Paix 2-pyridinone derivatives, having HIV inhibiting properties
MXPA06013315A (es) * 2004-05-17 2007-02-02 Tibotec Pharm Ltd 1,5-dihidro-pirido[3,2-b]indol-2-onas 4-sustituidas.
WO2006073973A2 (en) * 2004-12-31 2006-07-13 Reddy Us Therapeutics, Inc. Novel benzylamine derivatives as cetp inhibitors
BRPI0608907A2 (pt) 2005-05-10 2010-02-17 Itermune Inc método de modulação de sistema de proteìna cinase ativada por estresse
AU2006284900A1 (en) 2005-08-29 2007-03-08 Vertex Pharmaceuticals Incorporated 3, 5-disubstituted pyrid-2-ones useful as inhibitors of Tec family of non-receptor tyrosine kinases
CA2620269A1 (en) 2005-08-29 2007-03-08 Vertex Pharmaceuticals Incorporated 3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases
EP1919905B1 (en) 2005-08-29 2011-02-23 Vertex Pharmaceuticals Incorporated 3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-recptor tyrosine kinases
EP2020851A4 (en) * 2005-12-19 2009-09-02 Syngenta Ltd AROMATIC HETEROCYCLIC COMPOUNDS SUBSTITUTED AS FUNGICIDES
JP5539216B2 (ja) 2007-11-20 2014-07-02 メルク・シャープ・アンド・ドーム・コーポレーション 非ヌクレオシド系逆転写酵素阻害剤
US8304413B2 (en) 2008-06-03 2012-11-06 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US20110184029A1 (en) * 2008-07-14 2011-07-28 Korea Research Institute Of Chemical Technology Pyridone derivatives as non-nucleoside reverse transcriptase inhibitors
US8318737B2 (en) 2009-09-02 2012-11-27 Canthera Therapeutics Inc. Compounds and compositions for treating cancer
US8349832B2 (en) * 2009-09-02 2013-01-08 Canthera Therapeutics Compounds and compositions for treating cancer
CN102001994B (zh) * 2010-10-22 2014-07-09 北京大学 吡啶酮类hiv-1逆转录酶抑制剂的制备及其应用
CN103288719A (zh) * 2012-03-05 2013-09-11 苏州欧凯医药技术有限公司 非核甘艾滋病毒抑制物-吡啶酮类先导体的合成
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
KR102373700B1 (ko) 2014-04-02 2022-03-11 인터뮨, 인크. 항섬유성 피리디논
EP3186242B1 (en) 2014-08-29 2021-10-06 Tes Pharma S.r.l. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
KR102645602B1 (ko) * 2018-12-18 2024-03-07 머크 샤프 앤드 돔 엘엘씨 Hiv 감염된 세포에 대한 선택적 세포독성제로서의 피리미돈 유도체
CA3141143A1 (en) * 2019-05-22 2020-11-26 Merck Sharp & Dohme Corp. Pyridinone derivatives as selective cytotoxic agents against hiv infected cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ238576A (en) * 1990-06-18 1994-12-22 Merck & Co Inc Pyridinone derivatives, preparation and pharmaceutical compositions thereof
US5308854A (en) * 1990-06-18 1994-05-03 Merck & Co., Inc. Inhibitors of HIV reverse transcriptase
FR2737496B1 (fr) * 1995-07-31 1997-12-19 Centre Nat Rech Scient 4-aryl-thio-pyridin-2(1h)-ones, medicaments les contenant et leurs utilisations dans le traitement de maladies liees aux vih 1 et 2

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA013740B1 (ru) * 2004-09-17 2010-06-30 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Новые пиридиноновые производные и их применение в качестве позитивных аллостерических модуляторов mglur2-рецепторов

Also Published As

Publication number Publication date
SK16072000A3 (sk) 2002-04-04
HRP20000716A2 (en) 2001-06-30
KR20010087128A (ko) 2001-09-15
CZ20003978A3 (cs) 2001-09-12
WO1999055676A1 (en) 1999-11-04
DE69932611T2 (de) 2007-10-11
DE69932611D1 (de) 2006-09-14
US6451822B1 (en) 2002-09-17
ATE334966T1 (de) 2006-08-15
EP1073637A1 (en) 2001-02-07
AU4137899A (en) 1999-11-16
CA2330304A1 (en) 1999-11-04
ID27502A (id) 2001-04-12
NO20005387L (no) 2000-12-04
ZA200006037B (en) 2002-01-25
EE200000620A (et) 2002-04-15
CN1303378A (zh) 2001-07-11
US6683079B2 (en) 2004-01-27
NO20005387D0 (no) 2000-10-26
US20030125340A1 (en) 2003-07-03
HUP0101595A2 (hu) 2001-11-28
HUP0101595A3 (en) 2002-12-28
IL139239A0 (en) 2001-11-25
NZ508297A (en) 2002-12-20
MXPA00010490A (es) 2002-10-17
BR9909976A (pt) 2000-12-26
AP2000001991A0 (en) 2000-12-31
PL343685A1 (en) 2001-08-27
TR200003113T2 (tr) 2001-05-21
JP2002513004A (ja) 2002-05-08
EP1073637B1 (en) 2006-08-02
BG104984A (en) 2001-07-31

Similar Documents

Publication Publication Date Title
RU2000129671A (ru) Производные 3-(амино- или аминоалкил) пиридинона и их применение для лечения болезней, связанных с ВИЧ
RU2001102777A (ru) Оксазоло-, тиазоло- и селеназоло [4,5-с] -хинолин-4-амины и их аналоги
JP2001526269A5 (ru)
CO4910164A1 (es) Derivados de naftiridinas
WO2002018324A3 (en) Immunoregulatory compounds, derivatives thereof and their use
JP2006500394A5 (ru)
CA2089767A1 (en) Pyridinyl thiadiazolyl- and oxadiazolyl derivatives
JP2006528621A5 (ru)
JP2012511588A5 (ru)
JP2005538111A5 (ru)
JP2007501779A5 (ru)
RU96113098A (ru) Производные 5,6-дигидропирона в качестве ингибитора протеазы и антивирусные средства
KR900016216A (ko) 1-아자바이시클로[3.2.0]헵-2텐-2-카르복실산 화합물
TW354787B (en) 2-carbocyclic and 2-heterocyclic quinoline-4-carboxylic acids and salts thereof useful as immunosuppressive agents
JP2002515427A5 (ru)
RU2004118423A (ru) Производные бензотиазола в качестве лигандов рецептора аденозина
JP2004525183A5 (ru)
PT1173413E (pt) Utilizacao de derivados do acido 2,4-diamino-3-hidroxicarboxilicos como inibidores de proteassoma
RU96105063A (ru) Оксатиоланы, способ их получения и содержащая их фармацевтическая композиция
RU2001128671A (ru) Тиенопиримидиновые производные, их получение и применение
ATE358128T1 (de) Vorbeugende oder therapeutische mittel gegen gastrische oder ösophageale regurgitation
KR880009923A (ko) 질소함유 헤테로사이클릭 메탄올의 아릴옥시메틸 유도체 및 그의 에테르
SI1050531T1 (en) Pyridine and piperidine derivatives for treating neurodegenerative diseases
HUP0203640A2 (hu) Eljárás obesitas-ellenes és antidiabetikus tulajdonságokkal rendelkező (aril-etanol)-amin-származékok előállítására
NO178025C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive (benzhydryloksyetylpiperidyl)alifatiske syrederivater